In this study we looked at clinical outcomes of patients who underwent cardioversion in the non-interventional Global Anticoagulant Registry in the FIELD-AF (GARFIELD-AF). 44 201 patients were included in an analysis comparing patients who received a baseline cardioversion with those who did not (two years follow-up), and 7175 patients were included in an analysis comparing patients who received direct current cardioversion and those who had pharmacological cardioversion throughout the study time (one year follow-up).
       We found that a small proportion were treated with a baseline cardioversion (14.9%). Direct current cardioversion was performed twice as often as pharmacological cardioversion, and there appeared to be no major difference in outcome events for these two cardioversion modalities. For the overall cardioversion group, after adjustments for confounders, a significantly lower risk of mortality was found in patients who received cardioversion at baseline compared with those who did not (propensity score weighted HR 0.74 (95% CI 0.63-0.86) from baseline to one year follow-up and 0.77 (0.64-0.93) from one year to two year follow-up). Read more.

Pope MK, Hall TS, Schirripa V, Radic P, Virdone S, Pieper KS, Le Heuzey JY, Jansky P, Fitzmaurice DA, Cappato R, Atar D, Camm AJ, Kakkar AK; GARFIELD-AF investigators.

Categories: NEWS